Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series
Hiroyuki Kamei 1, 3*, Hanae Yamada 3, Masakazu Hatano 1, 2, 3, Manako Hanya 3, Shigeki Yamada 2, Nakao Iwata 1
1Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan, 2Department of Clinical Pharmacy, Fujita Health University School of Medicine, Aichi, Nagoya, Japan, 3Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan
Received: May 16, 2018; Revised: July 13, 2018; Accepted: July 31, 2018; Published online: July 31, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
Keywords: schizophrenia, antipsychotic agents, polypharmacy, patient satisfaction